Under the
Evotec intends to use the grant to initiate clinical studies assessing the safety and efficacy of the compound and to determine the optimal dose-range in healthy volunteers as well as COVID-19 patients.
Dr
About PRROTECT
To prepare against future pandemics, Evotec has initiated the global networking initiative PRROTECT (pandemic Preparedness and Rapid RespOnse TEChnology PlaTform). PRROTECT builds on Evotec's existing anti-viral therapeutics portfolio and leverages the Company's platform to further broaden its existing modality-agnostic pipeline against viral threats, while at the same time accelerating R&D timelines for neutralising antibodies, and creating a flexible manufacturing network to deliver such therapeutics in the event of a future pandemic.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
SVP, Head of Global Investor Relations & ESG
T: +49 40 560 81 775
E: volker.braun@evotec.com
Investor Relations Manager
T: +49 40 560 81 839
E: anika.meier@evotec.com
Investor Relations Associate
T: +49 40 560 81 210
E: anja.benlekhal@evotec.com
Investor Relations & ESG Coordinator
T: + 49 40 560 81 857
E: Amelia.Gonzalez-Palacios@evotec.com
(C) 2022 Electronic News Publishing, source